Oral estramustine and oral etoposide for hormone-refractory prostate cancer

By Dimopoulos M.A.   Panopoulos C.   Bamia C.   Deliveliotis C.   Alivizatos G.   Pantazopoulos D.   Constantinidis C.   Kostakopoulos A.   Kastriotis I.   Zervas A.   Aravantinos G.   Dimopoulos C.  

Urology, Vol. 50, Iss. 5, 1997-11 ,pp. : 754-758

Elsevier

Access to resources Recommend Favorite

A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

By Pienta K.J.   Redman B.G.   Bandekar R.   Strawderman M.   Cease K.   Esper P.S.   Naik H.   Smith D.C.  

Urology, Vol. 50, Iss. 3, 1997-09 ,pp. : 401-407

Elsevier

Access to resources Recommend Favorite

The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group

By Samelis G.F.   Skarlos D.   Bafaloukos D.   Kosmidis P.   Anagnostopoulos A.   Aravantinos G.   Dimopoulos M.A.  

Urology, Vol. 61, Iss. 6, 2003-06 ,pp. : 1211-1215

Elsevier

Access to resources Recommend Favorite

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer

By Vaishampayan U.   Fontana J.   Du W.   Hussain M.  

Urology, Vol. 60, Iss. 6, 2002-12 ,pp. : 1050-1054

Elsevier

Access to resources Recommend Favorite

Open-label phase II study of ZD0473 in patients with metastatic hormone-refractory prostate cancer

By Tyrrell C.   Bullard S.   Barber J.   Graham J.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 158-158

Elsevier

Access to resources Recommend Favorite